{"name":"Jonathan A. Bernstein, MD","slug":"jonathan-a-bernstein-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dupilumab Prefilled Syringe","genericName":"Dupilumab Prefilled Syringe","slug":"dupilumab-prefilled-syringe","indication":"Moderate-to-severe atopic dermatitis","status":"marketed"}]}],"pipeline":[{"name":"Dupilumab Prefilled Syringe","genericName":"Dupilumab Prefilled Syringe","slug":"dupilumab-prefilled-syringe","phase":"marketed","mechanism":"Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of IL-4 and IL-13 cytokines involved in type 2 inflammation.","indications":["Moderate-to-severe atopic dermatitis","Moderate-to-severe asthma with type 2 inflammation","Chronic rhinosinusitis with nasal polyps","Allergic rhinitis","Eosinophilic esophagitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxNbU12ZXNlekp4WV9pZW1pdnVrdWExOWVtUWFKY0ZaTFllZVo5aEhrQThOdEt0cTZOUVU1aTVKUjlSZzRxaGlUZHpkM0tmUlpMdW9QMDlUQ0t4cl9uQWJ4TjgtS0loT2ZhRmZjQVhUT0E4cjl2SGpnMTZXWEZaU0FoN2J4ckdzOGFyYUZkOUFLLW9MOUIxLWZBZUhFdUUxUVFPbURWQndLX2VMTTdjOE0ydDZxa1hkV0ZsUHdZNlNyWGxYTnZNY3ZWYU9XTEZ1ZDl6YUs4LVQwWmJKM1lVYzlmb1VCdUF0NlJKN0tVX3U3RkpYLWVVTF9wR0hLQlVESERKb1ZzLV90cVMtYXpxaFY2MDNMV2RFYkF0c3JwN3g5UQ?oc=5","date":"2026-03-02","type":"trial","source":"Business Wire","summary":"KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - Business Wire","headline":"KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBrNWY0X3FXcEg4R29YM0J2MEJuV0h4NW1JcWZDZzhHMldpVTFuWnZoQklfOWdvdXJSaXhRV0tEdDltNWp4RkpwVXNMUl9wcXQwRWJIXzljNjlnamJ3Zm41bmtrVHdxX2xMSGJQRGVKN0tiX2pNQmppTmRqLXBxMnc?oc=5","date":"2025-12-15","type":"regulatory","source":"Medscape","summary":"Hereditary Angioedema: Clinical Decision-Making and Emerging Therapies - Medscape","headline":"Hereditary Angioedema: Clinical Decision-Making and Emerging Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQbHRYamo2RnZQVlFYOUwyWGxlN0YxTEFDTkg0Wm1McXU3ZGg2M21oSktSZE9kNUFJLW9lMlo4UktWeEVmSWdtTHd0cDhob0ZJNGpuT1JudVFnaHlmSktrY2hSNXRFa2diQXZJOW1lVUdFbG1vUEx5Uk5HMVp1VjBGWXhUU2l1SmlPX0ljVXA4M082Q3ctNHFhTEdHUXg1OWlNZ1JlVA?oc=5","date":"2025-12-01","type":"regulatory","source":"Healio","summary":"Long-term Prophylaxis| Hereditary Angioedema - Healio","headline":"Long-term Prophylaxis| Hereditary Angioedema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQbmZacG9nd3VWQTZ3d2NHWnZoeWFLbHhLeGpJbkp2dHRuMUQyZEpyMWZxak02MGtzNlBMczhDWFZNaGdMa1gybE9TMDRYOXZWaUNDMk53TUc4ZHEtN3hScGVoSGx5UTNSOHpoR3FSTXROQkJJS3dmbllqbThVaVpFNzJobDhVTlV1eXlxT2JsVm1jd0JVbnpKTjlBRzRzYU90djRsYWR2WQ?oc=5","date":"2025-11-19","type":"pipeline","source":"HCPLive","summary":"Povorcitinib 75 mg Rapidly Reduces Itch and Hives in CSU, With Jonathan Bernstein, MD - HCPLive","headline":"Povorcitinib 75 mg Rapidly Reduces Itch and Hives in CSU, With Jonathan Bernstein, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPb2k1ak9iRFJ3NlMzLXhSUnZIZVhyakxWTWJJYUdGMFpYb1RJRm9aM1VRc05qSXg1YjFIZG1xWEFoZ1dIbzd0bG0tcHFfUGxLenhrTHlJaXdzTzNqQkhBZ3B4bk96Nl9TbmZMdTlHQ3g4REtIX3BRbUYtQjJGSWxMbzhvcTFicEVrd0hWaTJ6c1pPQ2E3ekhZZmZjZmY0SDEyMWVhQmM0aUFhdktSbnNwMTdIXzVhTzRmY2ExYlJmZ04wZ2l0Qm01Y2JkU3lzX3QzZDBCam5aaXdEZw?oc=5","date":"2025-11-19","type":"pipeline","source":"Healio","summary":"Povorcitinib shows potential in achieving disease control in chronic spontaneous urticaria - Healio","headline":"Povorcitinib shows potential in achieving disease control in chronic spontaneous urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPNTNMcEN6SHBUeEp0TS0yMklpSV9iWTA2eHdPNXY2THhEMWNjNk9JcGpTd013NVo5U2o4UGJUaW9HaENTbnJrR05LTnBjUVBuVlZKa2NlYkoyN1pfX0J6cnVmM2JvbUhGR0ZxaGptSS1ucFdBTmpEMGcxUVhuZFB6MC1HbTJUbEkwd3U0RkNNcVJuY0k1cFFBNUJ6SnZaaUE?oc=5","date":"2025-03-17","type":"pipeline","source":"Parkinson's News Today","summary":"Right Brain Bio to repurpose anticancer medication for Parkinson’s - Parkinson's News Today","headline":"Right Brain Bio to repurpose anticancer medication for Parkinson’s - Parkinson's News Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOYUNWakFJRGR2WDVJV19RVzZnNFRFeFdfaVRhdE8weWpkd3hMMjg4SVAybVZGVmZITmdIb0RhS0pQUE9FeVB1cVdFTkRfRjBxOWVWWUFUa3psSmhxU2w1QkFuaTQzOFl1cUNQeW90NlJuMWQ3WWFUUVNtaUhYLWpJV1pia0NSVV9hNS1iVC1DeDd1MktFUXNIWk9yT0thVkRGYjlnd2Z0UUFNMkVTZktWTzVHSXRVS2Z0Z3ptSjZNUVJaYjFVRHhRZmZhNFRKdlE0VE5oLUxxcTh2b2poZnh6YUpVbHc4X25yM1B1YWU5c1FJZEdnSWlHV1Z2a3FpWFFkLVVldlRPTFUzdUFJSjh4Y2VSaEwzallVdUJKMmtwM0l1eS1xS3lXLTRIQjlWQQ?oc=5","date":"2025-03-12","type":"trial","source":"BioSpace","summary":"In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease - BioSpace","headline":"In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNNGRKUDJOa0JjTWI5VHA0N3dwaF94Ny1XU0JhV0ZJVHVPRUp3aC1xWEZGU2xFSWtCYUU0Z1BOUGNCcjFCOHM3NDA0eHdSVXF1aU9iSW9DT2h3eXQ1b3l2cm8zbTJINnY2TmZ2VnNubTljQTNqMzBSQTNhcExIMHh1dHluaTRER3ZoU2V0M1dWdmFUYUljLUJ3V2txWE90aWRYUTFRUUkyMm9pVGFOY0c1UmNQTzFkY3FUUnJ4enJqaFlkamdHUGIxR0NQbmYyRzFvQWhySQ?oc=5","date":"2023-03-16","type":"regulatory","source":"Healio","summary":"On-demand sebetralstat treatment reduces hereditary angioedema attack symptoms, severity - Healio","headline":"On-demand sebetralstat treatment reduces hereditary angioedema attack symptoms, severity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPU1lZZERwOTN1LXV6TVFhZ2hqSXpzQVFDWGhkNnlqcHJBbjNOMEtYa1hLMnNQSXMtbS10cngyTHBPY3FZN1prNHBGckZUQkZxSnFVdzBacS1BYzI3bS1veFoxN0IxanhFOVIwaXc3R1l0QUFnSlprOEVwaVNTNm5kZjIyUHRmT1lCMmFhdGM5LXd3Vm84MzJYblBKOS1EYUEyX2d5UWlIbHlVUTZVQ0N2RV9fcnd5dw?oc=5","date":"2023-01-31","type":"pipeline","source":"Healio","summary":"Incoming AAAAI president outlines agenda for his administration - Healio","headline":"Incoming AAAAI president outlines agenda for his administration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1zWkdOZ2ZsTzFCZVBNblpyNVNpaHE3c2FwOHluUlVnb3FvTEMxZ0gzOEhnWlJwQ3NFNzNNSXV1Y3FIWU5RdkJPSWQ0WXlaOWhoT2o1eF9mRHVxMmo2UjBR?oc=5","date":"2022-03-16","type":"regulatory","source":"NEJM","summary":"Inhibition of Prekallikrein for Hereditary Angioedema - NEJM","headline":"Inhibition of Prekallikrein for Hereditary Angioedema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE95Q2FGaW5KUzdnYUpXT0QzemV0dno0U0hqQVJheFBIRzBRaTVjNWJJV1dTWmh3RldiR1hfeFNyT3VzUXdNRTE2VV9OcmdYc3RGcGtRSGlzS2JZVjRfSEpB?oc=5","date":"2019-10-02","type":"pipeline","source":"NEJM","summary":"Ligelizumab for Chronic Spontaneous Urticaria - NEJM","headline":"Ligelizumab for Chronic Spontaneous Urticaria","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE8wM25hVFh2V215Y0tVeUIyaWVSOE9UeVdHY0ptTVN2QTkxLWs5VmdXNzE1dm9iWUdRVXJrYWx0alU3SURNa0kwSzBxdTVuV1lKRVpHZXpxZjl6RWRrWFdwRw?oc=5","date":"2017-02-23","type":"regulatory","source":"NEJM","summary":"Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis - NEJM","headline":"Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}